A team from McMaster will use Sartorius' multicolumn chromatography system to develop a process for purifying therapeutic viruses that will be more cost-effective than current options, Sartorius said.

Chromatography is a way to purify compounds in the field of biomanufacturing. The company's system consists of a parallel processing protocol that makes it more efficient from both a resource and cost standpoint.

The collaboration is intended to support the United Nations' sustainable development goals (SDGs), according to Sartorius. The project will also provide student training opportunities at the company's research and development centers in North America and Europe.

"This partnership with McMaster University will lead to impactful research that will make important treatments available at a greater scale," said Brandon Corbett, PhD, a research scientist at Sartorius. "We see this as a way to expand our research development and bring SDG-aligned pharmaceuticals to Canadian and global markets."

Sartorius buys viral vector media company Xell for $59M
Sartorius Stedim Biotech has acquired cell culture company Xell, which is headquartered in Bielefeld, Germany.

Sartorius acquires majority stake in CellGenix
Life science company Sartorius has acquired a 51% stake in reagent manufacturer CellGenix through its subsidiary Sartorius Stedim Biotech.

CAR-NK cells hold promise for solid tumors
A new cancer immunotherapy that leverages the ability of natural killer (NK) cells to discriminate between cancer and normal cells has shown promise in...

Sartorius expands biopharma manufacturing in Slovenia
Sartorius plans to expand production facilities for purification products for vaccines and therapies at its facility in Ajdovscina, Slovenia.

How will summer weather shape the spread of COVID-19?
New research shows that while higher temperatures and humidity can slow the spread of COVID-19, longer hours of sunlight are associated with a higher...